This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Omburtamab is an anti-CD276 (B7-H3) antibody being investigated for use in various solid human tumours.

Generic Name
Omburtamab
DrugBank Accession Number
DB15635
Background

CD276 (B7-H3) is a B7/CD28 immunoglobulin superfamily member frequently expressed among solid human tumours.1,2 Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.3

Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Omburtamab

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

CD276 (also known as B7-H3) is a member of the B7/CD28 immunoglobulin superfamily with possible co-stimulatory and co-inhibitory roles in T cell-mediated immunity.1 Despite low to absent expression on most healthy cells, CD276 is frequently highly expressed among solid human tumours.1,2 Omburtamab, a murine anti-B7-H3 antibody, and its humanized forms bind to the CD276 FG loop thought to be important in co-inhibitory functions.1,3 Omburtamab also facilitates direct antibody-directed cellular cytotoxicity (ADCC) of CD276-expressing tumour cells.1 Recent experiments using chimeric antigen receptor (CAR) T cells and bispecific killer cell engager (BiKE)-redirected natural killer cells demonstrated efficacy against NSCLC in vitro and in vivo.2 Hence, targeting CD276 appears to be an appealing option for overcoming immunotherapy blockade in solid tumours.

TargetActionsOrganism
ACD276 antigen
binder
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
XQL6783S5T
CAS number
1895083-75-6

References

General References
  1. Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK: Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem. 2015 Dec 11;290(50):30018-29. doi: 10.1074/jbc.M115.679852. Epub 2015 Oct 20. [Article]
  2. Liu J, Yang S, Cao B, Zhou G, Zhang F, Wang Y, Wang R, Zhu L, Meng Y, Hu C, Liang H, Lin X, Zhu K, Chen G, Luo KQ, Di L, Zhao Q: Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021 Jan 29;14(1):21. doi: 10.1186/s13045-020-01024-8. [Article]
  3. Kaplon H, Muralidharan M, Schneider Z, Reichert JM: Antibodies to watch in 2020. MAbs. 2020 Jan-Dec;12(1):1703531. doi: 10.1080/19420862.2019.1703531. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Malignant Peritoneal Neoplasm / Primary Peritoneal Cancer1
2, 3RecruitingTreatmentCNS Metastases / Leptomeningeal Metastases / Neuroblastoma (NB)1
1CompletedOtherBrain Stem Gliomas / Cancer Brain1
1Not Yet RecruitingTreatmentDIPG1
1, 2Not Yet RecruitingTreatmentLeptomeningeal Metastasis / Solid Tumors, Adult1
1, 2RecruitingTreatmentMedulloblastoma, Childhood1
Not AvailableAvailableNot AvailableCentral Nervous System/Leptomeningeal Neoplasms1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Binder
Curator comments
Omburtamab binds to the FG loop of CD276 (B7-H3).
General Function
May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. May be involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. Could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy. Both isoform 1 and isoform 2 appear to be redundant in their ability to modulate CD4 T-cell responses. Isoform 2 is shown to enhance the induction of cytotoxic T-cells and selectively stimulates interferon gamma production in the presence of T-cell receptor signaling.
Specific Function
Signaling receptor binding
Gene Name
CD276
Uniprot ID
Q5ZPR3
Uniprot Name
CD276 antigen
Molecular Weight
57235.005 Da
References
  1. Ahmed M, Cheng M, Zhao Q, Goldgur Y, Cheal SM, Guo HF, Larson SM, Cheung NK: Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3. J Biol Chem. 2015 Dec 11;290(50):30018-29. doi: 10.1074/jbc.M115.679852. Epub 2015 Oct 20. [Article]

Drug created at March 07, 2020 20:12 / Updated at November 27, 2021 01:19